| P50 | author | Peter Dervan | Q907746 |
| P2093 | author name string | Jerzy Szablowski | |
| | Patrick J Frost | |
| | Veena S Mysore | |
| P2860 | cites work | The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. | Q37884379 |
| | Oxygen sensing, homeostasis, and disease | Q37914865 |
| | Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. | Q39129256 |
| | The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. | Q39802320 |
| | Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan | Q39813872 |
| | Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. | Q39896259 |
| | A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. | Q40053351 |
| | AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells | Q40224641 |
| | Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice | Q40542205 |
| | Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface | Q41857906 |
| | Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. | Q42141137 |
| | Solid-phase synthesis of DNA binding polyamides on oxime resin | Q44022836 |
| | Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. | Q44123722 |
| | Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. | Q44746790 |
| | Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug | Q45851460 |
| | Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. | Q46541959 |
| | A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect | Q47934995 |
| | Hypoxia and activated VEGF/receptor pathway in multiple myeloma | Q54658355 |
| | Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44 | Q71709369 |
| | Prognostic value of bone marrow angiogenesis in multiple myeloma | Q74216118 |
| | Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma | Q84587252 |
| | Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia | Q24524140 |
| | Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex | Q24559347 |
| | HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia | Q24671941 |
| | Molecular basis of the VHL hereditary cancer syndrome | Q28220414 |
| | ONCOMINE: a cancer microarray database and integrated data-mining platform | Q28255103 |
| | Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice | Q28588885 |
| | In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model | Q33362103 |
| | Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. | Q33829094 |
| | Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. | Q33863055 |
| | A C-14 labeled Py-Im polyamide localizes to a subcutaneous prostate cancer tumor | Q34053649 |
| | Biological consequences of tumor hypoxia | Q34275624 |
| | Bone marrow angiogenesis and progression in multiple myeloma. | Q34292940 |
| | Novel therapies targeting the myeloma cell and its bone marrow microenvironment | Q34461557 |
| | Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model | Q34526773 |
| | A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways | Q35163974 |
| | Metabolic signature identifies novel targets for drug resistance in multiple myeloma | Q35612105 |
| | Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis | Q35628969 |
| | Anti-VEGF/VEGFR therapy for cancer: reassessing the target | Q35910772 |
| | The updated biology of hypoxia-inducible factor | Q36001994 |
| | Bone marrow microenvironment and the identification of new targets for myeloma therapy | Q36162703 |
| | Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide | Q36342812 |
| | Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 |
| | Hypoxia signalling in cancer and approaches to enforce tumour regression | Q36488739 |
| | Regulating cellular oxygen sensing by hydroxylation. | Q36509378 |
| | Role and regulation of prolyl hydroxylase domain proteins | Q37079729 |
| | Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to fol | Q37106652 |
| | Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist | Q37695740 |
| | Direct measurement of local oxygen concentration in the bone marrow of live animals | Q37698984 |
| | Treatment options for relapsed and refractory multiple myeloma | Q37853735 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P921 | main subject | hypoxia | Q105688 |
| | multiple myeloma | Q467635 |
| P304 | page(s) | 253-266 | |
| P577 | publication date | 2016-01-22 | |
| P1433 | published in | Molecular Cancer Research | Q2751014 |
| P1476 | title | A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity | |
| P478 | volume | 14 | |